Dianthus Therapeutics to Participate in Three Upcoming Healthcare Investor Conferences
Dianthus Therapeutics (Nasdaq: DNTH) has announced its participation in three major healthcare investor conferences. CEO Marino Garcia will present corporate overviews at the Guggenheim Healthcare Innovation Conference (November 11, 1:30 p.m. ET, Boston), Jefferies Global Healthcare Conference (November 19, 9:00 a.m. GMT, London), and 7th Annual Evercore HealthCONx Conference (December 4, 10:50 a.m. ET, Coral Gables). Live webcasts will be available on the company's website under the Investors section.
Dianthus Therapeutics (Nasdaq: DNTH) ha annunciato la sua partecipazione a tre importanti conferenze per investitori nel settore sanitario. Il CEO Marino Garcia presenterà una panoramica aziendale al Guggenheim Healthcare Innovation Conference (11 novembre, 13:30 ET, Boston), al Jefferies Global Healthcare Conference (19 novembre, 9:00 GMT, Londra) e al 7° Annual Evercore HealthCONx Conference (4 dicembre, 10:50 ET, Coral Gables). Saranno disponibili webcast dal vivo sul sito web dell'azienda nella sezione Investitori.
Dianthus Therapeutics (Nasdaq: DNTH) ha anunciado su participación en tres importantes conferencias de inversores en el sector de la salud. El CEO Marino Garcia presentará una visión general de la empresa en la Conferencia de Innovación en Salud de Guggenheim (11 de noviembre, 13:30 ET, Boston), en la Conferencia Global de Salud de Jefferies (19 de noviembre, 9:00 GMT, Londres) y en la 7ª Conferencia Anual HealthCONx de Evercore (4 de diciembre, 10:50 ET, Coral Gables). Las retransmisiones web en vivo estarán disponibles en el sitio web de la empresa en la sección de Inversores.
다이안투스 치료제 (Nasdaq: DNTH)는 3개의 주요 헬스케어 투자자 회의에 참여한다고 발표했습니다. CEO 마리노 가르시아는 구겐하임 헬스케어 혁신 회의 (11월 11일, 1:30 p.m. ET, 보스턴), 제퍼리즈 글로벌 헬스케어 회의 (11월 19일, 9:00 a.m. GMT, 런던) 및 제7회 에버코어 헬스CONx 회의 (12월 4일, 10:50 a.m. ET, 코랄 게이블스)에서 기업 개요를 발표할 예정입니다. 회사 웹사이트의 투자자 섹션에서 실시간 웹캐스트를 볼 수 있습니다.
Dianthus Therapeutics (Nasdaq: DNTH) a annoncé sa participation à trois grandes conférences pour investisseurs dans le secteur de la santé. Le PDG Marino Garcia présentera des aperçus de l'entreprise lors de la Conférence sur l'Innovation en Santé de Guggenheim (11 novembre, 13h30 ET, Boston), de la Conférence Mondiale de Santé de Jefferies (19 novembre, 9h00 GMT, Londres) et de la 7ème Conférence Annuelle Evercore HealthCONx (4 décembre, 10h50 ET, Coral Gables). Des webinaires en direct seront disponibles sur le site Web de l'entreprise dans la section Investisseurs.
Dianthus Therapeutics (Nasdaq: DNTH) hat seine Teilnahme an drei bedeutenden Investorenkonferenzen im Gesundheitswesen angekündigt. CEO Marino Garcia wird Unternehmensüberblicke auf der Guggenheim Healthcare Innovation Conference (11. November, 13:30 ET, Boston), der Jefferies Global Healthcare Conference (19. November, 9:00 GMT, London) und der 7. jährlichen Evercore HealthCONx Conference (4. Dezember, 10:50 ET, Coral Gables) präsentieren. Live-Webcasts werden auf der Unternehmenswebsite im Bereich Investoren verfügbar sein.
- None.
- None.
NEW YORK and WALTHAM, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company’s participation and corporate overview presentations by Marino Garcia, Chief Executive Officer, at the following healthcare investor conferences during November and December 2024:
- Guggenheim Healthcare Innovation Conference on November 11 at 1:30 p.m. ET in Boston, MA
- Jefferies Global Healthcare Conference on November 19 at 9:00 a.m. GMT in London
- 7th Annual Evercore HealthCONx Conference on December 4 at 10:50 a.m. ET in Coral Gables, FL
Live webcasts of the Company’s presentations at these three conferences may be accessed under “News and Events” in the Investors section of the Dianthus Therapeutics website.
About Dianthus Therapeutics
Dianthus Therapeutics is a clinical-stage biotechnology company dedicated to designing and delivering novel, best-in-class monoclonal antibodies with improved selectivity and potency. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who are leading the development of next-generation antibody complement therapeutics, aiming to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases.
To learn more, please visit www.dianthustx.com and follow us on LinkedIn.
Contact
Jennifer Davis Ruff
Dianthus Therapeutics
jdavisruff@dianthustx.com
FAQ
When is Dianthus Therapeutics (DNTH) presenting at the Guggenheim Healthcare Conference in 2024?
What investor conferences is Dianthus Therapeutics (DNTH) attending in November-December 2024?
Where can investors watch Dianthus Therapeutics (DNTH) conference presentations?
